Manchester, September 9th 2005
11:00 – 11:15
Dr. Sarah Tabrizi
A brief overview of biomarkers in Huntington’s disease andwhat constitutes the ideal biomarker.
Presentations on Non-imaging Biomarkers Approaches in Huntington’s disease
Nature and Progress of the High Q Sponsored Biomarkers Projects.
Allan Tobin, High Q Foundation
Metabonomic Approaches to Identification of Biomarkers in Huntington’s disease.
Elaine Holmes, Imperial College, London
11:45 – 12:00
Cambridge HD Researchers’ Approaches to Identification of Biomarkers in HD
Andrew Michel, University of Cambridge
12:00 – 12:15
Identification of CSF orexin levels as a biomarker for Huntington’s disease.
Asa Peterson, Lund University, Sweden
Abnormalities of the HPA Axis in Huntington’s disease.
Maria Bjorkqvist, Lund University, Sweden
12:30 – 12:45
Epigenetic Gene Control Mechanisms in the Development and Progression
of Huntington’s disease – how this may be useful in identification of
biomarkers in Huntington’s disease.
Pernette Verschure, University of Amsterdam, NDL
Approx time for buffet lunch
13.15 – 13.30
Tracking Biomarkers in Mouse Pre-clinical Trials
Gillian Bates, King’s College London
Proteomic markers of Neurodegeneration in mouse models of disease.
Claus Zabel, University of Berlin
Proteomic Approaches to Biomarker Identification in Huntington’s
disease, and how interlinking current studies with HD imaging studies
Sarah Tabrizi, Institute of Neurology, London
Using the Best-Balance Constraint Procedure (BBCP) in the
interpretation of HD microarray data across species: preliminary results
Christian Neri, Department of Genomic Biology, Inserm, Paris
Microarray Approaches to Biomarker Identification to HD I
Angela Hodges, University of Cardiff
Microarray Approaches to Biomarker Identification to HD II
Ruth Luthi-Carter,University of Lausanne
on recent papers
Strand et al. Gene expression in Huntington's disease skeletal muscle: a potential biomarker.
Hum Mol Genet. 2005 Jul 1;14(13):1863-76.
Borovecki et al Proc Natl Acad Sci U S A. 2005 Aug
Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease.
These will be discussed by the whole working party but will be led by
Ruth Luthi-Carter, Angela Hodges and Lesley Jones, all who have
expertise in array approaches. They will evaluate these two papers and
we will all discuss how the data should be validated.
Collection of Samples within Euro-HD – blood, urine, muscle and CSF and validation of small studies – how to move forward
- Comparing the use of imaging with the wet biomarkers approach
- How to take forward identification of Biomarkers within the Euro- HD consortium.